COMMUNIQUÉS West-GlobeNewswire

Aveanna to Participate at the Jefferies Healthcare Services Conference
09/09/2025
ATLANTA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Jefferies Healthcare Services Conference in Nashville on [...]
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
09/09/2025
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine [...]
MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors
09/09/2025
Betty Aldworth and Ismail Lourido Ali bring decades of combined experience in drug policy leadership, psychedelic advocacy, and movement building As Co-Executive Directors, Aldworth and Ali reflect MAPS' legacy [...]
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
09/09/2025
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, [...]
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
09/09/2025
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 ® , (Smallpox [...]
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
09/09/2025
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- [...]
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
09/09/2025
UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE [...]
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
09/09/2025
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year [...]
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
09/09/2025
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical- [...]
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
09/09/2025
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade [...]
Breckenridge Brewery Awarded Silver Certification by the Colorado Green Business Network for Excellence in Sustainability Practices
09/09/2025
LITTLETON, Colo., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Breckenridge Brewery , a craft brewery owned by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is proud to announce it has received the Silver [...]
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
09/09/2025
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Assumes Presidency of EUROPACCESS, Enhancing Access to Innovative Medicines
09/09/2025
WATFORD, United Kingdom and BERWYN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CHAPPER healthcare , AscellaHealth’s global pharmaceutical wholesaler, distributor and commercialization service provider, announces its [...]
Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies
09/09/2025
Newly released data shows that nine in ten babies lack critical gut microbes needed for healthy development. Persephone’s Daily Synergistic Synbiotic, built on the largest and most comprehensive U.S. infant gut [...]
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
09/09/2025
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual- [...]
RYBREVANT®▼ (amivantamab) en association avec LAZCLUZE®▼ (lazertinib) réduit la résistance acquise à l’osimertinib dans le traitement de première intention du cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
09/09/2025
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET observées avec les ITK de l’EGFR 1 BEERSE, BELGIQUE, Sept. 09, 2025 [...]
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases
09/09/2025
Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September 09, 2025 – Scenic [...]
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
09/09/2025
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, [...]
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
09/09/2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targeted therapy with [...]

Pages